

Appendix 2. Management actions per 100 heavy menstrual bleeding problems managed by patient age group (April 2008–March 2016)

	Rate per 100 heavy menstrual bleeding problems managed, n (95% CI)				
	Age group				All ages
	12–24 years (n = 291)	25–34 years (n = 224)	35–44 years (n = 630)	45–54 years (n = 553)	12–54 years (n = 1698)
Non-pharmaceutical management					
Clinical treatments	26.8 (21.2, 32.4)	20.1 (14.4, 25.8)	18.4 (15.2, 21.6)	21.7 (17.7, 25.7)	21.1 (18.9, 23.4)
Counselling/advice/education	23.0 (17.8, 28.3)	17.4 (12.3, 22.5)	17.1 (14.0, 20.3)	19.2 (15.5, 22.9)	18.8 (16.7, 20.9)
Procedural treatments	3.1 (1.1, 5.1)	4.9 (1.8, 8.0)	3.3 (1.8, 4.9)	3.1 (1.6, 4.6)	3.4 (2.5, 4.3)
Local injection/infiltration	1.0 (0, 2.2)	1.3 (0, 2.9)	0.8 (0.1, 1.5)	1.1 (0.2, 1.9)	1.0 (0.5, 1.5)
Contraceptive device insertion/supply/removal	0	1.8 (0, 3.9)	1.4 (0.5, 2.4)	0.7 (0, 1.4)	1.0 (0.5, 1.5)
Pathology tests	71.1 (54.2, 88.0)	75.9 (56.5, 95.2)	94.3 (82.0, 106.5)	87.0 (73.9, 100.0)	85.5 (78.1, 92.9)
Full blood count	17.2 (12.6, 21.8)	18.8 (13.6, 23.9)	25.4 (21.9, 28.9)	22.8 (19.1, 26.5)	22.3 (20.2, 24.3)
Ferritin	15.8 (11.5, 20.1)	17.0 (12.0, 21.9)	21.9 (18.6, 25.2)	21.2 (17.6, 24.8)	20.0 (18.0, 21.9)
Thyroid function	10.3 (6.8, 13.8)	11.6 (7.4, 15.8)	10.6 (8.2, 13.1)	7.6 (5.4, 9.8)	9.7 (8.2, 11.2)
Hormone assay	4.1 (1.3, 7.0)	7.1 (2.2, 12.0)	11.0 (7.7, 14.2)	10.7 (7.1, 14.3)	9.2 (7.3, 11.0)
Coagulation studies	3.4 (1.4, 5.5)	1.8 (0, 3.5)	0.6 (0, 1.3)	1.1 (0.2, 2.0)	1.4 (0.8, 2.0)
Imaging tests	16.2 (11.7, 20.6)	25.4 (19.5, 31.4)	27.6 (24.0, 31.3)	28.6 (24.6, 32.6)	25.7 (23.4, 27.9)
Pelvic ultrasonography	14.8 (10.6, 18.9)	25.0 (19.1, 30.9)	26.5 (22.9, 30.1)	26.8 (23.0, 30.6)	24.4 (22.2, 26.5)
Referrals	8.6 (5.3, 11.8)	21.0 (15.7, 26.3)	24.6 (21.0, 28.2)	25.1 (21.2, 29.1)	21.6 (19.5, 23.6)
Obstetrician/gynaecologist	7.9 (4.8, 11.0)	18.3 (13.3, 23.4)	22.9 (19.4, 26.3)	22.8 (19.1, 26.5)	19.7 (17.7, 21.7)
Pharmaceutical management*	74.2 (66.6, 81.8)	45.5 (37.6, 53.4)	49.8 (45.1, 54.6)	47.6 (42.7, 52.4)	52.7 (49.7, 55.7)
Combined oral contraceptive pill†	35.4 (29.8, 41.0)	15.2 (10.4, 19.9)	12.4 (9.8, 14.9)	6.3 (4.3, 8.4)	14.7 (13.0, 16.4)
Levonorgestrel/ethinylloestradiol	24.4 (19.4, 29.4)	9.8 (5.9, 13.8)	7.9 (5.8, 10.0)	4.0 (2.3, 5.6)	9.7 (8.3, 11.1)
Cyproterone/ethinylloestradiol	3.1 (1.1, 5.1)	1.3 (0, 2.9)	0.5 (0, 1.0)	0.2 (0, 0.5)	0.9 (0.5, 1.4)
Drospirenone/ethinylloestradiol	4.1 (1.8, 6.4)	1.3 (0, 2.9)	1.7 (0.7, 2.8)	0.4 (0, 0.9)	1.6 (1.0, 2.3)
Norethisterone/ethinylloestradiol	3.4 (1.3, 5.5)	2.2 (0.3, 4.2)	1.1 (0.3, 1.9)	1.3 (0.3, 2.2)	1.7 (1.1, 2.3)
Tranexamic acid	7.2 (4.1, 10.3)	7.6 (4.1, 11.1)	7.3 (5.2, 9.4)	8.1 (5.8, 10.4)	7.6 (6.3, 8.9)
Norethisterone	6.9 (4.0, 9.8)	4.0 (1.4, 6.6)	6.2 (4.3, 8.1)	9.6 (7.0, 12.1)	7.1 (5.9, 8.4)
Medroxyprogesterone‡	3.8 (1.2, 6.4)	4.0 (0.6, 7.4)	4.6 (2.4, 6.8)	7.8 (4.7, 10.9)	5.4 (4.0, 6.9)
Depot medroxyprogesterone acetate†	2.4 (0.6, 4.2)	1.3 (0, 2.9)	0.8 (0.09, 1.5)	1.3 (0.3, 2.2)	1.3 (0.8, 1.8)
Levonorgestrel intrauterine system†	0	2.7 (0.5, 4.8)	5.6 (3.8, 7.3)	5.8 (3.8, 7.7)	4.3 (3.3, 5.3)
Nonsteroidal anti-inflammatory drugs†	9.6 (6.2, 13.0)	9.4 (5.6, 13.2)	7.8 (5.6, 10.0)	3.6 (2.0, 5.3)	6.9 (5.7, 8.2)
Mefenamic acid	8.6 (5.4, 11.8)	6.3 (3.1, 9.4)	5.6 (3.7, 7.4)	2.9 (1.4, 4.4)	5.3 (4.2, 6.4)
Iron therapy†	6.2 (3.4, 9.0)	2.7 (0.5, 4.8)	4.9 (3.2, 6.6)	6.5 (4.4, 8.6)	5.4 (4.3, 6.4)
Rate per 100 encounters where heavy menstrual bleeding problems managed					
Pap smears‡	2.7 (0.9, 4.6)	9.8 (5.9, 13.7)	14.4 (11.6, 17.3)	10.8 (8.1, 13.6)	10.7 (9.1, 12.2)
Pregnancy test (blood and urine) †	3.4 (1.3, 5.5)	4.9 (2.1, 7.7)	2.1 (1.0, 3.2)	0.4 (0, 0.9)	2.1 (1.4, 2.8)

*Includes all medications prescribed, supplied or recommended for over-the-counter purchase

†Classification according to the Coding Atlas of Pharmaceutical Substances and the Anatomical Therapeutic Classification System outlined in Appendix 1

‡Includes all pregnancy tests and Pap smears performed or ordered
CI, confidence interval